Literature DB >> 16871701

Distribution of mosquito species in areas with high and low incidence of classic Kaposi's sarcoma and seroprevalence for HHV-8.

V Ascoli1, L Facchinelli, L Valerio, A Zucchetto, L Dal Maso, M Coluzzi.   

Abstract

The 'promoter-arthropod' hypothesis, which postulates that exposure to the bites of certain species of haematophagous arthropods is an environmental risk cofactor linked to human herpes virus 8 (HHV-8) and Kaposi's sarcoma, was investigated in the Po River valley, northern Italy. The presence and density of adult female mosquitoes (Diptera: Culicidae) was determined by CDC light trap catches in two adjacent districts, at variance with respect to Kaposi's sarcoma incidence and HHV-8 seroprevalence. A total of 3910 specimens belonging to 11 species was collected in 34 rural sites (six municipalities) representative of the two districts. Five of these species are considered to be possible 'promoters' because of the irritation their bites cause humans: Aedes vexans (Meigen) and Ae. caspius (Pallas) (87% of sampled promoters), Culex modestus Ficalbi, Culiseta annulata (Schrank) and Coquillettidia richiardii (Ficalbi). Six are probable 'non-promoters': Cx. pipiens s.l., Cx. martinii Medschid, Anopheles claviger (Meigen), An. maculipennis s.l., An. plumbeus Stephens and Uranotaenia unguiculata Edwards. The density of promoters by site was correlated with the incidence rates of Kaposi's sarcoma at the district level (Pearson's r = 0.33, P = 0.06) and at the municipal level (r = 0.50, P< 0.01). Similar correlations emerged for non-promoters (r = 0.48, P< 0.01 and r = 0.42, P = 0.01, respectively). The density of promoters was higher than that of non-promoters in sites with livestock (odds ratio, OR = 2.8, 95% CI 2.2-3.6) and in municipalities with Kaposi's sarcoma cases (OR = 2.5, 95% CI 1.7-3.5). The study provides additional evidence of the association between the density of some mosquito species and Kaposi's sarcoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871701     DOI: 10.1111/j.1365-2915.2006.00624.x

Source DB:  PubMed          Journal:  Med Vet Entomol        ISSN: 0269-283X            Impact factor:   2.739


  6 in total

1.  Prevalence of toscana and sicilian phlebovirus antibodies in classic Kaposi sarcoma case patients and control subjects in sicily.

Authors:  Emanuele Amodio; Melissa Valentini; Gianni Gori-Savellini; Rosalia Maria Valenti; Nino Romano; James J Goedert; Maria Grazia Cusi
Journal:  J Infect Dis       Date:  2011-09-07       Impact factor: 5.226

2.  Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women.

Authors:  Alison M Elliott; Denise Whitby; Robert Newton; Katie Wakeham; Emily L Webb; Ismail Sebina; Lawrence Muhangi; Wendell Miley; W Thomas Johnson; Juliet Ndibazza
Journal:  Infect Agent Cancer       Date:  2011-09-30       Impact factor: 2.965

Review 3.  Updated occurrence and bionomics of potential malaria vectors in Europe: a systematic review (2000-2021).

Authors:  Michela Bertola; Matteo Mazzucato; Marco Pombi; Fabrizio Montarsi
Journal:  Parasit Vectors       Date:  2022-03-15       Impact factor: 3.876

4.  Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002).

Authors:  V Ascoli; G Minelli; M Kanieff; R Crialesi; L Frova; S Conti
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

5.  Dangerous liaisons: molecular basis for a syndemic relationship between Kaposi's sarcoma and P. falciparum malaria.

Authors:  Katelyn L Conant; Anita Marinelli; Johnan A R Kaleeba
Journal:  Front Microbiol       Date:  2013-03-12       Impact factor: 5.640

6.  Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda.

Authors:  Katie Wakeham; Emily L Webb; Ismail Sebina; Angela Nalwoga; Lawrence Muhangi; Wendell Miley; W Thomas Johnston; Juliet Ndibazza; Denise Whitby; Robert Newton; Alison M Elliott
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.